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THE FUTURE OF GENERIC BIOLOGICS: 
SHOULD THE UNITED STATES “FOLLOW-ON” 
THE EUROPEAN PATHWAY? 
INGRID KALDRE1
ABSTRACT 
 The United States is embarking on a biotechnology drug revolution. 
In the last few decades, biotech drugs have saved millions of lives, and the 
market for these miracle cures continues to grow at an astronomical rate. 
Unfortunately, as the market for biotech drugs is skyrocketing, drug prices 
are following suit. As Congress strives to make these new drugs more 
affordable, it must not ignore significant safety concerns unique to these 
revolutionary therapies. Congress should follow the lead of the European 
Union to create an accessible pathway for generic forms of biotech drugs 
that includes strict regulatory measures to ensure drug safety and efficacy.  
INTRODUCTION 
¶1 Though it might appear a product of modern science, biotechnology 
has been utilized by humans for thousands of years.2 In 4000 B.C., humans 
first used “biotechnology” to ferment beer and to leaven bread through the 
use of yeast.3 Though our history is filled with other such creative uses of 
organisms to manufacture products,4 the term “biotechnology” was not used 
in print until the 1900’s.5 Today, biotechnology has been seamlessly 
integrated into our daily life, affecting everything from the foods we eat to 
the clothes we wear.6 
¶2 Biotechnology plays a paramount role in the creation of new 
prescription drugs and vaccines. Biotechnological drugs (“biologics”) are 
                                                     
1 J.D. candidate, Duke University School of Law, 2009; B.S. in Physics, Duke 
University, 2006. The author is grateful for the insightful suggestions of Arti 
Rai, Professor of Law at Duke University.
2 Biotechnology is defined as the use and manipulation of living organisms and 
their biological processes to create useful products. Oxford English Dictionary 
210 (2d ed. 1989). 
3 Biotechnology Industry Org., Time Line, 
http://bio.org/speeches/pubs/er/timeline.asp (last visited Jan. 12, 2008). 
4 See id. 
5 See id. 
6 National Health Museum, Tools for Genetic Ingenuity: How Can You 
Remember These Uses of Biotechnology?, 
http://www.accessexcellence.org/RC/AB/BA/aapost/remember.html (last visited 
Jan. 12, 2008). 
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unique because they can replace or enhance natural proteins produced by 
the body.7 To date, the biotech drug industry has created more than 400 
biotech drugs and vaccines, which help treat more than 200 diseases.8 These 
drugs and vaccines target life-threatening diseases such as cancers, 
HIV/AIDS, hepatitis C, and autoimmune disorders,9 as well as heart disease 
and stroke.10 Because of their ability to boost our body’s ability to cope 
with disease, biologics have already helped more than 325 million sick 
people.11 
¶3 While the future of biotech drugs holds much promise, two factors 
may hamper their future development: unique safety concerns and cost. 
First, biologics present unique safety concerns not faced by “traditional” 
small-molecule chemical drugs. The most serious safety concern, unique to 
biologics, is “immunogenicity.”12 Immunogenicity is a patient’s adverse 
antibody reaction to a drug in which the body perceives a drug to be a 
foreign microorganism or virus.13 Immunogenicity proved fatal in 2001, 
when several patients died of pure red cell aplasia after a form of the 
biotech drug erythropoietin caused a severe antibody reaction.14 The 
patients became allergic to all forms of erythropoietin, including the form 
found in their own bodies, and died when their bodies could not make red 
blood cells.15 
¶4 The second factor which may hamper the future development of 
biotech drugs is their skyrocketing cost. From 1998 to 2006, the average 
cost of biologics has gone up 505 percent.16 And today, the cost of these 
drugs is astronomical. For example, the biotech drug Avastin—a treatment 
                                                     
7 Michal Nowicki, Basic Facts About Biosimilars, 30 KIDNEY BLOOD PRESSURE 
RES. 267, 267 (2007). 
8 Zach Patton, Complex Rx, GOVERNING MAG., Oct. 2007, at 58. 
9 Cyril T. Zaneski, “Miracle” Biotech Drugs Growing in Use and Cost, BALT. 
SUN, Mar. 16, 2004, at 1A. 
10 PHARMACEUTICAL RES. & MFR. OF AMER., 418 BIOTECHNOLOGY MEDICINES 
IN TESTING PROMISE TO BOLSTER THE ARSENAL AGAINST DISEASE 1 (2006), 
available at http://www.phrma.org/files/Biotech%202006.pdf. 
11 Kenneth B. Seamon, Lecture at the University of Cambridge: Biotechnology 
Medicinal Products: Opportunities and Challenges, slide 6 (Oct. 2, 2007), 
available at 
http://www.ifpma.org/pdf/2007_10_02_Geneva_Bio_Forum_KSeamon.pdf. 
12 See Bryan A. Liang, Endangering the Public Health, DRUG DISCOVERY & 
DEV. 56, 56 (April 2007) [hereinafter Liang, Public Health].  
13 Bryan A. Liang, Regulating Follow-On Biologics, 44 HARV. J. ON LEGIS. 363, 
375 (2007) [hereinafter Liang, Follow-On Biologics]. 
14 Liang, Public Health, supra note 12, at 56. 
15 Id. 
16 Patton, supra note 8, at 58. 
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for breast and lung cancer—costs a patient $100,000 per year.17 Other 
biotech drugs, such as Cerezyme—a treatment for a life-threatening enzyme 
deficiency—costs patients from $200,000 to $500,000 per year.18 
¶5 One solution to the problem of rising drug costs could be the 
approval of generic biopharmaceutical drugs. Generics can produce 
significant reductions in cost because their development costs are often 
much lower.19 Currently, although a legislative framework approving 
generic biotech drugs does not exist, such a framework has existed for 
small-molecule chemical drugs for over twenty years.20 For small-molecule 
drugs, generic versions of brand-name drugs have resulted in cheaper drugs: 
the savings from generic chemical drugs has been 30% to 80% off of the 
price of their brand-name counterparts.21 In the case of generic biologics, 
some experts predict only modest savings because there is little room to cut 
corners during development and production.22 Other experts are more 
optimistic,23 arguing that even a 10% to 20% reduction in cost would save 
patients billions of dollars.24 
¶6 Although high costs have motivated U.S. legislators to begin 
considering a regulatory pathway for generic biotech drugs recently, the 
European Union (E.U.) has already implemented a regulatory pathway for 
“biosimilars.” Safety concerns, unveiled by the tragic incidence of pure red 
cell aplasia in 2001,25 caused the E.U. to set up a “rigorous regulatory 
system,” which requires mandatory clinical testing and periodic review after 
a biosimilar is released.26 
¶7 In the U.S., safety concerns have led to a debate over whether 
clinical trials should be mandated by statute or whether the regulatory 
                                                     
17 Alex Berenson, A Cancer Drug Shows Promise, at a Price That Many Can’t 
Pay, N.Y. TIMES, Feb. 15, 2006, at A1. 
18 Kathleen Jaeger, Creating a Workable Biogenerics Pathway for Patients, 5 J. 
GENERIC MEDS. 1, 1 (2007), available at http://www.palgrave-
journals.com/jgm/journal/v5/n1/full/4950094a.html. 
19 Huub Schellekens, How Similar Do ‘Biosimilars’ Need to Be?, 22 NATURE 
BIOTECHNOLOGY, 1357, 1358 (2004) [hereinafter Schellekens, How Similar].  
20 See generally Drug Price Competition and Patent Term Restoration Act of 
1984, Pub. L. No. 98-417, 98 Stat. 1585. 
21 Generic Pharmaceutical Association, Generics: Lower Cost, 
http://www.gphaonline.org/AM/Template.cfm?Section=FAQs&Template=/CM/
HTMLDisplay.cfm&ContentID=2497 (last visited Apr. 2, 2008). 
22 Patton, supra note 8, at 58. 
23 Some experts predict savings from $50 billion to $71 billion over a 10 year 
period. See id. 
24 Generic Pharmaceutical Association, supra note 21. 
25 For a brief discussion of this incident, see supra text accompanying notes 14–
15. 
26 Liang, Public Health, supra note 12, at 56. 
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process should be left up to the Food and Drug Administration (“FDA”). 
Innovator companies are strong proponents of mandatory clinical trials, 
while generic drug manufacturers believe in a more fluid regulatory 
regime.27 Stranded in the middle of this heated controversy are U.S. 
legislators. This article argues that Congress should follow the E.U.’s lead 
to set up a strict regulatory system for generic biologics, due to unique 
safety concerns inherent in their production. Congress should mandate 
human clinical tests and pharmacovigilance for every generic biologic until 
we better understand these drugs and their effects on the body. 
I. THE BIOPHARMACEUTICAL DRUG REVOLUTION 
¶8 In the last ten years, the sale of biologics has skyrocketed. In 2000, 
biologics sales accounted for only eleven percent of total drug sales in the 
U.S.28 Five years later, this number rose to eighteen percent. 29 And by 
2010, it is estimated that this number will increase to twenty-six percent.30 
¶9 Biologics are drugs or vaccines, created from the manipulation of a 
living organism.31 This manipulation often relies on biotechnology to attain 
a genetic sequence that will produce a desired therapy or prophylactic.32 
Scientists use tools such as gene splicing33 to manipulate the genetic code 
of living organisms—like plant and animal cells, viruses, bacteria, and 
yeasts.34 Because the production of these new drugs depends on modern 
technology, biologics have not been on the market for long. For example, 
the most widely used biologic, recombinant human insulin, was not 
approved by the FDA until 1982.35 
¶10 Their fairly recent introduction into the drug market is only one of 
the many factors that distinguish biologics from the traditional small-
molecule chemical drugs. For example, most chemical drugs are housed in 
capsules and delivered to patients orally in pill form.36 Alternatively, 
                                                     
27 See Huub Schellekens, Biosimilar Therapeutic Agent: Issues with 
Bioequivalence and Immunogenicity, 34 EUROPEAN J. OF CLINICAL 
INVESTIGATION 797, 798 (2004). 
28 Patton, supra note 8, at 58.  
29 Id. 
30 Id. 
31 Biotechnology Industry Organization, Glossary, 
http://bio.org/speeches/pubs/er/glossary_b.asp (last visited Apr. 2, 2008). 
32 See Lisa J. Raines, Bad Medicine: Why the Generic Drug Regulatory 
Paradigm Is Inapplicable to Biotechnology Products, J. BIOLAW & BUS., 
Autumn 2002, at 1, 8. 
33 PHARMACEUTICAL RES. AND MFR. OF AMER., supra note 10, at 1. 
34 Nowicki, supra note 7, at 267.  
35 Patton, supra note 8, at 58.  
36 Liang, Follow-On Biologics, supra note 13, at 366. 
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biologics, which are composed of enzymes, must be inhaled or injected 
because they are susceptible to deterioration in the stomach and intestines.37 
A susceptibility to deterioration also requires biopharmaceutical companies 
to follow strict manufacturing and storage guidelines.38 
¶11 A biologic’s unique sensitivity to its environment can be attributed 
to (1) its complex structure, (2) its mode of action, and (3) the manner in 
which it is manufactured.39 First, biologics are much more complex than 
chemical drugs. A biologic originates in a living organism and is composed 
of various proteins with varying gene sequences.40 These proteins often 
show a considerable amount of non-uniformity.41 Consequently, although 
the structure of a chemical drug is well-defined,42 a biologic’s complex 
composition makes it difficult to characterize.43 These differences in 
composition result in a biologic’s “fragile 3-dimensional structure,” and a 
chemical drug’s “well-characterized 1-dimensional structure.”44 In addition, 
a biologic’s unique complexity is also evident in its large size. An average 
biologic drug molecule is 100 to 1,000 times larger than a chemical drug 
molecule.45 A comparison of their relative sizes demonstrates this 
difference: an aspirin molecule (small-molecule drug) weighs 180 Da, while 
an interferon-β (biologic) weighs 19,000 Da.46 
¶12 Second, in addition to its complex structure and size,47 a biologic’s 
unique sensitivity to its environment can be attributed to its mode of action, 
                                                     
37 Nowicki, supra note 7, at 268. 
38 Id. 
39 Id. 
40 Id. A Dalton (Da) is a unit of mass used to express atomic and molecular 
mass. It is one twelfth of the mass of a carbon-12 (12C) atom at rest and in its 
ground state, which is approximately the mass of a hydrogen atom.  
41 Schellekens, How Similar, supra note 19, at 1357. 
42 Id.  
43 See Christopher Webster et al., Can There Be Abbreviated Applications, 
Generics, or Follow-On Products?, BIOPHARM INT’L, Jul. 2003, at 28, 34–35.. 
44 Nowicki, supra note 7, at 268 (citing M. Karpusas, A. Whitty, L. Runkel & P. 
Hochman, The Structure of Human Interferon-Beta: Implications for Activity, 54 
CELLULAR & MOLECULAR LIFE SCI. 1203 (1998)). 
45 Nowicki, supra note 7, at 268. 
46 Id. 
47 It is important to note that biologics differ in structure, size, and complexity 
not only from chemical drugs but also from each other. Insulin and human 
growth hormone, for example, are much simpler than more complex biologics. 
See Assessing the Impact of a Safe and Equitable Biosimilar Policy in the 
United States: Hearing of the Subcomm. on Health of the H. Comm. on Energy 
& Commerce, 110th Cong. (2007) [hereinafter Hearing of the Subcomm. on 
Health]. Their simpler structure makes these biologics more accessible to 
researchers than their more complex counterparts. See id. 
  
2008 DUKE LAW & TECHNOLOGY REVIEW No. 9 
which is much more complex than that of a chemical drug. In general, a 
biologic can affect up to one-hundred physiological processes48 while a 
chemical drug will only affect a handful of processes in the body.49 In 
addition, a biologic’s structural complexity and complex mode of action 
make its effect on the human body hard to predict.50 
¶13 Third, a biologic’s sensitivity to its environment can be attributed to 
the manner in which it is manufactured. In general, due to its complexity 
and unique origins, a biologic is difficult and expensive to manufacture.51 
While a chemical process creates a chemical drug, the manufacture of a 
biotech drug requires the manipulation of genetic material and a biological 
process.52 Inherently more variable, this manipulation results each time in a 
unique product.53 
¶14 Due to the complexity and variability in the manufacture of 
biologics, a controlled environment and stringent safety review and testing 
are critical. During manufacturing, an average small-molecule drug may 
require 40–50 tests, while an average biologic requires up to 250 tests or 
more.54 Consequently, an average biologic might require up to five times 
the number of safety tests required for a small-molecule drug. 
¶15 Lastly, the complexity of biologics makes their manufacture much 
more expensive than the manufacture of chemical drugs.55 High 
manufacturing costs are a substantial reason for the skyrocketing cost of 
biologics56 as compared to small-molecule drugs. In the treatment of 
arthritis, for example, the most expensive small-molecule drug treatment 
costs $300 per patient per year, while Enbrel, a biologic arthritis treatment, 
can cost an average of $20,000 per patient per year. 57 
                                                     
48 Id. (“[R]ecombinant interferon, interacts with nearly 100 genes which makes 
its exact mode of action really difficult to predict and explore.”). 
49 Nowicki, supra note 7, at 267. 
50 See id. (“While chemical agents usually affect one or a few processes in the 
living organism, the biotechnological molecule . . . interacts with nearly 100 
genes which makes its exact mode of action really difficult to predict and 
explore.”). 
51 Id. at 268. 
52 Henry Grabowski, Iain Cockburn & Genia Long, The Market for Follow-On 
Biologics: How Will It Evolve?, 25 HEALTH AFFAIRS 1291, 1292 (2006). 
53 See Schellekens, How Similar, supra note 19, at 1357. 
54 Webster, supra note 43, § 16. 
55 Patton, supra note 8, at 58.  
56 BEN ROBERTS, SHOULD THE F.D.A. CREATE AN EXPEDITED APPROVAL 
PROCESS FOR GENERIC BIOLOGIC DRUGS? 5 (2007). 
57 Patton, supra note 8, at 58.  
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II. FOLLOW-ON BIOLOGICS MAY HELP CURB COSTS 
¶16 Follow-on biologics, the biotech equivalent of “generic” chemical 
drugs, are developed after an original biologic has lost patent protection and 
must be approved independent of the original.58 Follow-on biologics are 
also sometimes referred to as “generic biologics” 59 and are called 
“biosimilars” in the E.U.60 Even though terms such as “generic” might 
suggest that follow-ons are exact copies of the originals, in actuality these 
alternate versions are far from identical.61 They are created using a different 
manufacturing process and are born out of different cell lines than the 
original biologic.62 Consequently, follow-on biologics are not exact replicas 
of original biotech drugs, but they do treat the same medical condition and 
utilize the same mechanism of action as the original.63 
¶17 Currently, follow-on biologics go through the same clinical trials 
and testing as original biologics in order to get FDA approval.64 Many 
follow-on manufacturers do not begin this process until after the original 
biologic loses patent protection in order to ensure that their product does not 
infringe on the innovator’s patent.65 Because receiving FDA approval can 
be an expensive and timely process, the lack of an abbreviated regulatory 
pathway for follow-on biologics extends an originator’s patent beyond its 
statutory time limit.66 Due to identical manufacturing and testing costs, 
follow-on biologics are also not cheaper than the originals. An “abbreviated 
approval process” could allow follow-on companies to cut corners during 
the testing phase of manufacturing, thus lowering the price of biotech 
drugs.67 
¶18 An abbreviated approval process already exists for chemical 
drugs.68 This abbreviated process has resulted in 30% to 80% savings 
                                                     
58 See Webster, supra note 43, §3. 
59 Bruce S. Manheim, Jr., Patricia Granahan & Kenneth J. Dow, ‘Follow-On 
Biologics’: Ensuring Continued Innovation in the Biotechnology Industry, 25 
HEALTH AFFAIRS 394, 394 (2006).   
60 Nowicki, supra note 7, at 258. 
61 See Webster, supra note 43, at 29. 
62 Nowicki, supra note 7, at 268.  
63 Richard G. Frank, Regulation of Follow-on Biologics, 357.9 NEW ENG. J. 
MED. 841, 841 (2007).  
64 ROBERTS, supra note 56, at 11. 
65 Gregory N. Mandel, The Generic Biologics Debate: Industry’s Unintended 
Admission that Biotech Patents Fail Enablement, 11 VA. J.L. & TECH. 8, 23 
(2006). 
66 Id. 
67 ROBERTS, supra note 56, at 4. 
68 Id. at 2. 
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between chemical drugs and their brand-name counterparts.69 The 
abbreviated approval process for small-molecule chemical drugs was 
created in 1984 through the Drug Price Competition and Patent Term 
Restoration Act (“Hatch-Waxman Act”).70 In the case of generic chemical 
drugs, the Hatch-Waxman Act lowers the bar to gaining FDA approval if an 
applicant shows equivalency between his generic and a chemical drug 
already approved by the FDA.71 The statute provides that an applicant may 
file an Abbreviated New Drug Application (“ANDA”) for a generic version 
of a “drug which has been approved for safety and effectiveness” under 
§ 505 of the Federal Food, Drug, and Cosmetic Act (“FD&C Act”).72 A 
generic chemical drug that met a standard of “sameness” does not have to 
repeat human clinical tests that his predecessor had already completed to 
gain FDA approval.73 
¶19 As written, this statute did not include drugs licensed under § 351 
of the Public Health Service Act (“PHS Act”).74 Because the great majority 
of biologics are licensed under the PHS Act, 75 the Hatch-Waxman Act 
applies mostly to chemical drugs and not biologics.76 Only congressional 
action can create a regulatory scheme extending the Hatch-Waxman Act to 
include biologics licensed under the PHS Act.77 
III. EUROPE HAS ALREADY DEVELOPED A REGULATORY SCHEME 
FOR FOLLOW-ON BIOLOGICS 
¶20 In 2003, the E.U. passed legislation that established an abbreviated 
approval process for “biosimilars,” the European equivalent of follow-on 
biologics.78 This legislation empowered the European equivalent of the 
FDA, the European Medicines Agency (“EMEA”), to set guidelines for the 
approval of biosimilars.79 The European legislation further stated that the 
final decision to approve or reject a drug did not fall on the EMEA but on 
                                                     
69 Generic Pharmaceutical Association, supra note 21. 
70 Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in scattered sections 
of 15, 21, 28 & 35 U.S.C.). 
71 ROBERTS, supra note 56, at 2. 
72 See Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 
355 (2006). 
73 See Frank, supra note 63, at 841. 
74 See Public Health Service Act, 42 U.S.C. § 262 (2006). 
75 FDA, Omnitrope (somatropin [rDNA origin]): Questions and Answers, 
http://www.fda.gov/cder/drug/infopage/somatropin/qa.htm (last visited Jan. 12, 
2007). 
76 ROBERTS, supra note 56, at 9.  
77 See Grabowski, supra note 52, at 1292.  
78 See Should the U.S. Copy the Europeans? IP LAW & BUSINESS, May 2007. 
79 ROBERTS, supra note 56, at 55. 
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the European Commission (“EC”).80 In 2006, the EMEA guidelines took 
effect— mandating comparative human trials, one year of testing, and risk-
management plans.81 
¶21 In practice, a generic biologic manufacturer in Europe can now 
claim that a drug is “similar” to a biologic that has already been approved.82 
The manufacturer must then substantiate this claim by comparing the 
quality, safety, and efficacy of the new drug to the biologic already on the 
market.83 Most importantly, the manufacturer must demonstrate comparable 
immunogenicity,84 which often requires preclinical and clinical data.85 
Depending on the biologic, this demonstration of equivalency may require 
more trial patients than the original manufacturer needed to prove the drugs 
safety in the first place.86 
¶22 To date, the EC has approved two biosimilar applications and 
rejected one application.87 In April 2006, the Commission approved a 
generic human growth hormone, Omnitrope, and a few months later a 
second growth hormone, Valtropin.88 Also during the same time period, the 
EMEA rejected Alpheon, a hepatitis-C treatment, because it did not find the 
generic to be adequately “similar” to the reference product, Roferon-A.89 
¶23 Whether these new biosimilars have resulted in price savings has 
not yet been determined.  Some groups, like the International Alliance of 
Patients’ Organizations (IAPO), argue that the cost savings from biosimilars 
                                                     
80 Stephan Herrera, Biogenerics Standoff, 22 NATURE BIOTECHNOLOGY 1343, 
1344 (2004). 
81 See Bryan A. Liang, Generic Safety Risks, THE AMERICAN SPECTATOR, July 
25, 2007, http://www.spectator.org/dsp_article.asp?art_id=11780 (last visited 
Oct. 14, 2008) [hereinafter Liang, Safety Risks]. 
82 Schellekens, How Similar, supra note 19, at 1357. 
83 Id. 
84 Id. at 1358. 
85 Should the U.S. Copy the Europeans?, supra note 78. 
86 Schellekens, How Similar, supra note 19, at 1357. 
87 Nowicki, supra note 7, at 267. 
88 Gary C. Messplay & Colleen Heisey, Follow-On FDA Watch, “Follow on 
Biologics: A regulatory update,” Contract Pharma A regulatory update, 
WORLD SERVICES GROUP, Jun. 1, 2006, 
http://www.worldservicesgroup.com/publications.asp?action=article&artid=129
1 (last visited Jan. 12, 2008). 
89 Kirsty Barnes, BioPartners’ biosimilar drug knocked back in Europe, 
DRUGRESEARCHER.COM, Jul. 3, 2006, 
http://www.drugresearcher.com/news/ng.asp?id=68818-biopartners-emea-
biosimilar-biologic-drugs-interferon (last visited Jan. 12, 2008).  
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is currently unknown.90 While others, like the European Generics 
Medicines Association (EGA), disagree. EGA posits that initial pricing 
estimates for the European-biosimilar Omnitrope suggest a 20% to 30% 
cost savings.91 
IV. THE U.S. IS WORKING ON ITS OWN REGULATORY PATHWAY FOR 
FOLLOW-ON BIOLOGICS 
¶24 In the U.S., generic drug manufacturers and state and local 
governments are lobbying for Congress to create a regulatory pathway for 
follow-on biologics. Generic drug manufacturers insist there is a need for an 
abbreviated approval process for generic biologics and argue that the 
European model is too “onerous.”92 State and local governments are also 
pushing for a regulatory pathway.93 State Medicaid programs spend more 
than $500 million per year on recombinant human insulin alone. 94 As the 
high cost of follow-on biologics is taking its toll on state treasuries, state 
governments are looking to Congress for a solution.95 
¶25 Congress is currently considering legislation that would extend the 
abbreviated approval pathway that exists for generic small-molecule drugs 
to generic biologics.96 Both House and Senate committees have been 
working to draft legislation that takes into account the competing interest of 
their constituents as well as balancing cost and safety.97 Though there has 
not been a consensus in the House,98 the Senate Committee on Health, 
Education, Labor and Pensions (“HELP Committee”) has drafted a bill that 
would create an abbreviated regulatory pathway for generic biologics.99 The 
                                                     
90 EU Generic Firms Respond to “Biosimilar” Criticisms, PHARMACY TIMES, 
Jan. 2007, at 46, available at 
http://www.pharmacytimes.com/issues/articles/2007-01_4284.asp. 
91 EU Generic Firms Respond to “Biosimilar” Criticisms, PHARMACY TIMES, 
Jan. 2007, at 46, available at 
http://www.pharmacytimes.com/issues/articles/2007-01_4284.asp. 
92 Should the U.S. Copy the Europeans?, supra note 78. 
93 Patton, supra note 8, at 58 (“The National Governors Association, among 
other groups, has asked Congress and the FDA to establish a regulatory 
framework for generic biologics.”). See generally National Governors 
Association, Medicaid Reform Policy (EC-16), at 16.2.1, available at 
http://www.nga.org (follow “Policy Positions” hyperlink; then follow “EC-16” 
hyperlink).  
94 Patton, supra note 8, at 58. 
95 See id. 
96 See ROBERTS, supra note 56, at 2. 
97 See id. at 6. 
98 Drew Armstrong, House-Passed FDA Authorization Heads for Contentious 
Conference, 2007 CQ WEEKLY 2117. 
99 ROBERTS, supra note 56, at 13–14. 
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Biologics Price Competition and Innovation Act of 2007 was introduced in 
the Senate in June 2007.100 
¶26 This Bill amends § 351 of the PHS Act to create an abbreviated 
approval process for generic biologics.101  It creates a process similar to the 
ANDA process for generic small-molecule drugs under the Hatch-Waxman 
Act. The language of the Bill states that the main requirement is a 
demonstration of “interchangeability” between the generic and the reference 
drug.102 The Bill does not mandate clinical testing and pharmacovigilance 
for every generic biologic, but instead leaves drug application review up to 
the FDA on a case-by-case basis.103 
¶27 The language of the Bill suggests that the HELP Committee intends 
to take a more liberal approach to approval than did the E.U. Unlike the 
E.U., the HELP Committee proposal does not put emphasis on clinical 
human studies, testing, and risk-management.104 By focusing on a showing 
of interchangeability, and not sameness, the Bill would allow for molecular 
differences between a reference product and its follow-on, significantly 
increasing the safety risks to patients.105 
V. IMMUNOGENICITY: A SAFETY CONCERN UNIQUE TO BIOLOGICS 
¶28 The HELP Committee Bill treats generic biologics much the same 
as the Hatch-Waxman Act treats generic small-molecule drugs. It thus 
ignores the unique safety concerns presented by biotech drugs. 
Immunogenicity, the body’s immune system response to a drug, is a safety 
concern that legislators did not face when creating the ANDA pathway for 
generic small-molecule drugs.106 In some cases, a patient’s immune system 
responds to proteins in biologics by releasing a large number of anti-protein 
antibodies.107 For vaccines, an adverse antibody response to a drug is 
desired.108 But for the majority of biologics, an antibody response will 
                                                     
100 See Biologics Price Competition and Innovation Act of 2007, S. 1695, 110th 
Cong., 1st Sess. (2007), available at http://thomas.loc.gov/cgi-
bin/query/z?c110:S.1695:. 
101 See id. 
102 See id. at § 2(3)(b). 
103 See generally id. 
104 Liang, Safety Risks, supra note 81. 
105 Id. 
106 See Liang, Public Health, supra note 12, at 56. See supra text accompanying 
notes 10–13. 
107 Raines, supra note 32, at 8. 
108 Liang, Public Health, supra note 12, at 56. 
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adversely affect the efficacy of the drug and can be toxic to the body. 109 In 
some cases, such immune responses can be life-threatening.110 
¶29 Differences in structure, composition, and complexity between 
small-molecule drugs and biologics make an identical regulatory approval 
process inconsistent and potentially dangerous. The relatively simple 
structure of small-molecule drugs allows generic manufacturers to create 
generic drugs with identical chemical compositions and modes of action.111 
Due to their “sameness” in composition, clinical tests performed on the 
original drug can reliably establish the safety and efficacy of the generic 
copy. On the other hand, the inherent structural complexity of biologics 
makes them virtually impossible to copy.112 Because a generic biologic has 
a different structure and mode of action than the original, clinical tests that 
measure a patient’s immune response to the originator drug cannot reliably 
be passed on to a generic.113 
¶30 The danger of an antibody reaction to a generic biologic is further 
complicated because our current technology cannot adequately predict 
immunogenicity.114 Immunogenicity is greatly influenced by a wide array 
of factors, including patient specific factors—such as genetics and general 
health.115 Additionally an antibody response to a biologic is not always 
apparent until more than a year of regular drug use.116 
¶31 Without the proper technology, the only way to measure an 
antibody response to a drug is through clinical studies.117 Recently Dr. Janet 
Woodcock, deputy commissioner and chief medical officer for the FDA, 
testified to the House that with today’s limited technology, human trials are 
necessary to protect against adverse antibody reactions.118 In some cases, 
clinical studies for a follow-on biologic require more patients than were 
required for the original.119 For example, when studying a follow-on 
biologic, researchers must not only test for antibody reactions to the new 
drug but also test for any antibody reactions that result from switching 
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treatments.120 The unpredictability of protein immunogenicity and the threat 
of serious health consequences demonstrate the importance of human trials 
and pharmacovigilance for every biologic that enters the market. 
¶32 In passing a regulatory pathway for follow-on biologics, Congress 
must consider whether to mandate clinical trials by statute for each and 
every generic biologic or whether to leave this decision up to the FDA on a 
case-by-case basis. Proponents of a more flexible standard, argue that 
leaving this decision in the hands of the FDA will be the most efficient 
because biologics vary in size and complexity and because standards will 
change as technology develops.121 Others argue that mandating clinical 
trials by statute will ensure safety at our current stage, a stage when 
immunogenicity is unpredictable and clinical trials are necessary even in the 
most common biologics.122 
CONCLUSION 
¶33 As Congress moves forward with passing a regulatory pathway for 
follow-on biologics, it should follow the E.U. lead by setting up a strict 
regulatory system that puts the safety of the American public first. Congress 
should consider the potentially dangerous implications of legislation like the 
HELP Bill, which applies the simplistic formulation of the Hatch-Waxman 
Act to complex follow-on biologics. Furthermore, it should mandate clinical 
trials by statute for every generic biologic instead of leaving this decision up 
to the FDA. In the European model, the EC acts as a check on the EMEA’s 
power to approve a biosimilar.123 Considering the diagnostic limitations in 
today’s technology, Congress should ensure that the FDA does not cut 
corners in approving follow-on biologics until researchers understand and 
can harness any adverse effects of biologics on the body. 
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